vs
Amerant Bancorp Inc.（AMTB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Amerant Bancorp Inc.的1.8倍（$207.3M vs $112.2M），Amerant Bancorp Inc.净利率更高（3.0% vs -62.0%，领先65.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 2.9%），Amerant Bancorp Inc.自由现金流更多（$129.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 10.1%）
阿梅兰特银行是一家注册于美国佛罗里达州的本土银行，总部坐落于佛罗里达州科勒尔盖布尔斯。目前该行在佛罗里达州共设有19家实体分行，通过自有运营及合作网络可提供超过5.5万台ATM的取款服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
AMTB vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.2M | $207.3M |
| 净利润 | $2.7M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 1.7% | -54.7% |
| 净利率 | 3.0% | -62.0% |
| 营收同比 | 2.9% | 25.9% |
| 净利润同比 | -84.0% | 3.5% |
| 每股收益（稀释后） | $0.08 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $112.2M | $207.3M | ||
| Q3 25 | $111.4M | $159.9M | ||
| Q2 25 | $110.3M | $166.5M | ||
| Q1 25 | $105.4M | $139.3M | ||
| Q4 24 | $87.6M | $164.6M | ||
| Q3 24 | $33.3M | $139.5M | ||
| Q2 24 | $98.8M | $147.0M | ||
| Q1 24 | $92.5M | $108.8M |
| Q4 25 | $2.7M | $-128.6M | ||
| Q3 25 | $14.8M | $-180.4M | ||
| Q2 25 | $23.0M | $-115.0M | ||
| Q1 25 | $12.0M | $-151.1M | ||
| Q4 24 | $16.9M | $-133.2M | ||
| Q3 24 | $-48.2M | $-133.5M | ||
| Q2 24 | $5.0M | $-131.6M | ||
| Q1 24 | $10.6M | $-170.7M |
| Q4 25 | 1.7% | -54.7% | ||
| Q3 25 | 17.1% | -106.9% | ||
| Q2 25 | 27.0% | -64.8% | ||
| Q1 25 | 14.6% | -102.6% | ||
| Q4 24 | 20.6% | -74.3% | ||
| Q3 24 | -185.8% | -94.6% | ||
| Q2 24 | 6.4% | -79.1% | ||
| Q1 24 | 14.6% | -151.9% |
| Q4 25 | 3.0% | -62.0% | ||
| Q3 25 | 13.2% | -112.8% | ||
| Q2 25 | 20.9% | -69.0% | ||
| Q1 25 | 11.3% | -108.5% | ||
| Q4 24 | 19.3% | -80.9% | ||
| Q3 24 | -144.6% | -95.7% | ||
| Q2 24 | 5.0% | -89.5% | ||
| Q1 24 | 11.4% | -156.8% |
| Q4 25 | $0.08 | $-1.28 | ||
| Q3 25 | $0.35 | $-1.81 | ||
| Q2 25 | $0.55 | $-1.17 | ||
| Q1 25 | $0.28 | $-1.57 | ||
| Q4 24 | $0.53 | $-1.34 | ||
| Q3 24 | $-1.43 | $-1.40 | ||
| Q2 24 | $0.15 | $-1.52 | ||
| Q1 24 | $0.31 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $938.8M | $-80.0M |
| 总资产 | $9.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $938.8M | $-80.0M | ||
| Q3 25 | $944.9M | $9.2M | ||
| Q2 25 | $924.3M | $151.3M | ||
| Q1 25 | $906.3M | $144.2M | ||
| Q4 24 | $890.5M | $255.0M | ||
| Q3 24 | $902.9M | $346.8M | ||
| Q2 24 | $734.3M | $432.4M | ||
| Q1 24 | $738.1M | $140.3M |
| Q4 25 | $9.8B | $1.5B | ||
| Q3 25 | $10.4B | $1.2B | ||
| Q2 25 | $10.3B | $1.3B | ||
| Q1 25 | $10.2B | $1.3B | ||
| Q4 24 | $9.9B | $1.5B | ||
| Q3 24 | $10.4B | $1.5B | ||
| Q2 24 | $9.7B | $1.6B | ||
| Q1 24 | $9.8B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $137.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $129.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | 115.2% | -48.6% |
| 资本支出强度资本支出/营收 | 6.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 50.71× | — |
| 过去12个月自由现金流最近4个季度 | $225.2M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $137.0M | $-99.8M | ||
| Q3 25 | $22.7M | $-91.4M | ||
| Q2 25 | $57.6M | $-108.3M | ||
| Q1 25 | $20.2M | $-166.5M | ||
| Q4 24 | $82.2M | $-79.3M | ||
| Q3 24 | $4.2M | $-67.0M | ||
| Q2 24 | $-2.3M | $-77.0M | ||
| Q1 24 | $2.8M | $-190.7M |
| Q4 25 | $129.2M | $-100.8M | ||
| Q3 25 | $21.7M | $-92.7M | ||
| Q2 25 | $56.3M | $-110.7M | ||
| Q1 25 | $18.0M | $-167.8M | ||
| Q4 24 | $74.8M | $-79.5M | ||
| Q3 24 | $2.6M | $-68.6M | ||
| Q2 24 | $-3.9M | $-79.0M | ||
| Q1 24 | $-694.0K | $-193.9M |
| Q4 25 | 115.2% | -48.6% | ||
| Q3 25 | 19.5% | -58.0% | ||
| Q2 25 | 51.0% | -66.5% | ||
| Q1 25 | 17.1% | -120.5% | ||
| Q4 24 | 85.3% | -48.3% | ||
| Q3 24 | 7.8% | -49.2% | ||
| Q2 24 | -3.9% | -53.7% | ||
| Q1 24 | -0.8% | -178.2% |
| Q4 25 | 6.9% | 0.5% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 2.1% | 1.0% | ||
| Q4 24 | 8.4% | 0.1% | ||
| Q3 24 | 4.8% | 1.2% | ||
| Q2 24 | 1.5% | 1.4% | ||
| Q1 24 | 3.8% | 3.0% |
| Q4 25 | 50.71× | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | 2.50× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 4.87× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.47× | — | ||
| Q1 24 | 0.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMTB
| Other | $58.0M | 52% |
| Commercial Portfolio Segment | $25.7M | 23% |
| Commercial Real Estate Portfolio Segment | $17.3M | 15% |
| Consumer Portfolio Segment | $11.1M | 10% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
